Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) – Pipeline Review, H2 2016’, provides in depth analysis on Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted pipeline therapeutics.

The report provides comprehensive information on the Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1)

The report reviews Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics and enlists all their major and minor projects

The report assesses Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Arno Therapeutics Inc

Nyken BV

Oncogenex Pharmaceuticals Inc

RESprotect GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) Overview 6

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Stage of Development 7

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Therapy Area 8

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Indication 9

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Products under Development by Companies 13

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Companies Involved in Therapeutics Development 22

Arno Therapeutics Inc 22

Nyken BV 23

Oncogenex Pharmaceuticals Inc 24

RESprotect GmbH 25

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Drug Profiles 26

apatorsen - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

AR-12 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

brivudine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

NYK-1112 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

NYK-1341 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Dormant Projects 39

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Discontinued Products 41

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Featured News & Press Releases 42

Oct 25, 2016: OncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2 Trial in Metastatic Bladder Cancer 42

Mar 01, 2016: RedHill Biopharma Provides Update on RP101 42

Jan 20, 2016: OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer 43

Dec 09, 2015: OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis 44

Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis 45

Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains 45

Sep 30, 2015: OncoGenex Announces Completion of Patient Enrollment in Borealis-2 Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer 46

Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference 47

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 48

Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition 49

Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 50

Jun 01, 2015: OncoGenex Announces Data from Borealis-1 Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer 51

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research 52

May 20, 2015: OncoGenex To Present Phase II Study Data On Apatorsen At ASCO 2015 Annual Meeting 53

May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 53

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Arno Therapeutics Inc, H2 2016 22

Pipeline by Nyken BV, H2 2016 23

Pipeline by Oncogenex Pharmaceuticals Inc, H2 2016 24

Pipeline by RESprotect GmbH, H2 2016 25

Dormant Projects, H2 2016 39

Dormant Projects (Contd..1), H2 2016 40

Discontinued Products, H2 2016 41

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports